Wong Hector R, Cvijanovich Natalie Z, Allen Geoffrey L, Thomas Neal J, Freishtat Robert J, Anas Nick, Meyer Keith, Checchia Paul A, Weiss Scott L, Shanley Thomas P, Bigham Michael T, Banschbach Sharon, Beckman Eileen, Harmon Kelli, Zimmerman Jerry J
1 Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Am J Respir Crit Care Med. 2014 Apr 15;189(8):940-6. doi: 10.1164/rccm.201401-0171OC.
Corticosteroids are prescribed commonly for patients with septic shock, but their use remains controversial and concerns remain regarding side effects.
To determine the effect of adjunctive corticosteroids on the genomic response of pediatric septic shock.
We retrospectively analyzed an existing transcriptomic database of pediatric septic shock. Subjects receiving any formulation of systemic corticosteroids at the time of blood draw for microarray analysis were classified in the septic shock corticosteroid group. We compared normal control subjects (n = 52), a septic shock no corticosteroid group (n = 110), and a septic shock corticosteroid group (n = 70) using analysis of variance. Genes differentially regulated between the no corticosteroid group and the corticosteroid group were analyzed using Ingenuity Pathway Analysis.
The two study groups did not differ with respect to illness severity, organ failure burden, mortality, or mortality risk. There were 319 gene probes differentially regulated between the no corticosteroid group and the corticosteroid group. These genes corresponded predominately to adaptive immunity-related signaling pathways, and were down-regulated relative to control subjects. Notably, the degree of down-regulation was significantly greater in the corticosteroid group, compared with the no corticosteroid group. A similar pattern was observed for genes corresponding to the glucocorticoid receptor signaling pathway.
Administration of corticosteroids in pediatric septic shock is associated with additional repression of genes corresponding to adaptive immunity. These data should be taken into account when considering the benefit to risk ratio of adjunctive corticosteroids for septic shock.
皮质类固醇常用于感染性休克患者,但它们的使用仍存在争议,且副作用问题也一直存在。
确定辅助性皮质类固醇对小儿感染性休克基因组反应的影响。
我们回顾性分析了现有的小儿感染性休克转录组数据库。在进行微阵列分析采血时接受任何全身性皮质类固醇制剂的受试者被归类为感染性休克皮质类固醇组。我们使用方差分析比较了正常对照组(n = 52)、感染性休克无皮质类固醇组(n = 110)和感染性休克皮质类固醇组(n = 70)。使用 Ingenuity 通路分析对无皮质类固醇组和皮质类固醇组之间差异调节的基因进行了分析。
两个研究组在疾病严重程度、器官衰竭负担、死亡率或死亡风险方面没有差异。无皮质类固醇组和皮质类固醇组之间有319个基因探针差异调节。这些基因主要对应于适应性免疫相关信号通路,相对于对照组被下调。值得注意的是,与无皮质类固醇组相比,皮质类固醇组的下调程度明显更大。在对应于糖皮质激素受体信号通路的基因中也观察到类似的模式。
在小儿感染性休克中使用皮质类固醇与适应性免疫相关基因的进一步抑制有关。在考虑辅助性皮质类固醇治疗感染性休克的风险效益比时,应考虑这些数据。